Isolation of the 3′R and 3′S diastereomers of fasciculic acid C from the Australian mushroom Hypholoma australianum

Hayton, Joshua B.; Ward, Benjamin T.; Elnaas, Ali R.; Zunk, Matthew; Holland, Darren C; May, Tom W.; Voser, Tanja M.; Abitbol, Arjuna; Cooper, Oren; Tiralongo, Joe; Grice, I. Darren; Carroll, Anthony R.; Tiralongo, Evelin

doi:10.1016/j.tetlet.2021.153294

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many mushroom species have had their primary and secondary metabolite profiles extensively investigated, for example, C. millitaris, I. obliquus, C. africanus, H. erinaceous , and various Ganoderma species ( Table 2 ). These species provide examples that mushroom NPs can alleviate neuroinflammation-mediated cell death, increase abnormal protein clearance, and promote anti-neuroinflammatory effects in both animal and cell models, without displaying cytotoxicity [ 112 , 113 , 114 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 ]. As seen in Table 2 , a wide variety of compounds have been at the forefront of recent ND research, including but are not limited to polysaccharides, variations of di, tri, sesqui, and lanostane-based terpenoids, and phenols.…”

Section: Mushroom Natural Products: Their Relevance In Ameliorating N...mentioning

confidence: 99%

Mushroom Natural Products in Neurodegenerative Disease Drug Discovery

Abitbol

Mallard

Tiralongo

et al. 2022

Cells

Self Cite

View full text Add to dashboard Cite

The variety of drugs available to treat neurodegenerative diseases is limited. Most of these drug’s efficacy is restricted by individual genetics and disease stages and usually do not prevent neurodegeneration acting long after irreversible damage has already occurred. Thus, drugs targeting the molecular mechanisms underlying subsequent neurodegeneration have the potential to negate symptom manifestation and subsequent neurodegeneration. Neuroinflammation is a common feature of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and multiple sclerosis, and is associated with the activation of the NLRP3 inflammasome, which in turn leads to neurodegeneration. Inflammasome activation and oligomerisation is suggested to be a major driver of disease progression occurring in microglia. With several natural products and natural product derivatives currently in clinical trials, mushrooms have been highlighted as a rich and largely untapped source of biologically active compounds in both in vitro and in vivo neurodegenerative disease models, partially supported by successful clinical trial evaluations. Additionally, novel high-throughput methods for the screening of natural product compound libraries are being developed to help accelerate the neurodegenerative disease drug discovery process, targeting neuroinflammation. However, the breadth of research relating to mushroom natural product high-throughput screening is limited, providing an exciting opportunity for further detailed investigations.

show abstract